Physician profile
Ian E Reed
NPI 1003336561
$757.05
in general payments reported to CMS, 2019-2025
11 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.68 · 2022: $38.74 · 2023: $69.59 · 2024: $18.99 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $178.71 | 2025 | |
| Novo Nordisk INC | $134.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $133.44 | 2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals Lp | $105.08 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $93.67 | 2023-2025 | |
| Exact Sciences Corporation | $32.80 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $18.99 | 2024 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $16.55 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.68 | 2025 | Voquezna |
| Boston Scientific Corporation | $14.18 | 2025 | Wavewriter Alpha Prime 16 |
| E.R. Squibb & Sons, L.L.C. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.